In September 2018, following agreements with the Government of the Republic of Uzbekistan, foreign investors resolved to build a state-of-the-art pharmaceutical manufacturing facility in Tashkent, fully aligned with international GMP (Good Manufacturing Practice) standards. To bring this ambitious vision to life, FE "BELPHARM" LLC was founded in January 2019, officially launching the project's implementation in October of the same year.
By 2023, both the first phase (beta-lactam antibiotics) and the second phase (solid dosage forms) of production were successfully completed. The triumph of this investment project was cemented by obtaining our Pharmaceutical Manufacturing License, alongside GMP Certificates from both the Republic of Uzbekistan and the Eurasian Economic Union. Today, these credentials stand as our guarantee that every medication produced on our lines adheres to the most rigorous global safety and quality protocols.